Table 2. Baseline characteristics of the British Society for Rheumatology Biologics Register (BSRBR) patients with rheumatoid arthritis (RA), by treatment group.
| Control (DMARD) (n = 2880) | All anti-TNFα (n = 9826) | p Value | Specific anti-TNFα treatment | ||||
| Etanercept (n = 3910) | Infliximab (n = 3206) | Adalimumab (n = 2710) | p Value | ||||
| Age, mean (SD) | 60.0 (12.4) | 56.2 (12.2) | <0.001 | 55.9 (12.2) | 55.9 (12.4) | 56.8 (11.9) | 0.005 |
| Female, % | 72% | 76% | <0.001 | 77% | 76% | 75% | 0.055 |
| Disease duration (years), median (IQR) | 7 (1 to 15) | 11 (6 to 19) | <0.001 | 12 (6 to 19) | 12 (6 to 19) | 11 (5 to 19) | 0.002 |
| Smoking, %: | |||||||
| Current | 24% | 22% | 0.002 | 21% | 22% | 24% | 0.036 |
| Former | 40% | 38% | 38% | 38% | 38% | ||
| Never | 36% | 40% | 41% | 40% | 38% | ||
| HAQ, median (IQR) | 1.6 (1.0 to 2.1) | 2.1 (1.8 to 2.5) | <0.001 | 2.1 (1.8 to 2.5) | 2.1 (1.8 to 2.5) | 2.0 (1.6 to 2.4) | <0.001 |
| DAS28, mean (SD) | 5.0 (1.3) | 6.6 (1.0) | <0.001 | 6.6 (1.0) | 6.6 (1.0) | 6.5 (1.0) | <0.001 |
| Calendar year, median (IQR) | 2004 (2004 to 2005) | 2003 (2003 to 2004) | <0.001 | 2004 (2003 to 2004) | 2003 (2002 to 2003) | 2004 (2003 to 2005) | <0.001 |
IQR, interquartile range.